Efficacy Study Measuring the Impact of Pregabalin on Peripheral Neuropathic Pain.

NCT00219544

Last updated date
Study Location
Pfizer Investigational Site
Calgary, Alberta, T2N 4N1, Canada
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Neuropathic Pain
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects presenting a diagnosis of peripheral neuropathic pain, defined as pain caused by a lesion of the peripheral nervous system manifesting with sensory symptoms and signs, for at least 6 months at screening.

- At baseline, subjects must have completed at least 4 daily pain diaries and must have a mean weekly pain score equal or greater than 4.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Presence of any of the following diagnoses: Cervical or lumbo-sacral radiculopathy;
Operated or non-operated chronic low back pain Carpal tunnel syndrome or any other
entrapment-related neuropathic pain (defined as pain associated with focal nerve
lesion produced by constriction or mechanical distortion of the nerve, within a
fibrous or fibro-osseous tunnel, or by a fibrous band) ; Complex regional pain
syndrome (type 1 and 2); Fibromyalgia.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Neuropathic PainA Study to Assess the Efficacy, Safety and Tolerability of Pregabalin in Patients With Symptoms of Neuropathic Pain NCT00301223
  1. Beijing,
  2. Cheng Du Si Chaun,
  3. Guang Zhou,
  4. Nan Jing, Jiang Su,
  5. Qing Dao Shan Dong,
  6. Shang Hai,
  7. Shanghai,
  8. Tian Jin,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Neuropathic PainEfficacy Study Measuring the Impact of Pregabalin on Peripheral Neuropathic Pain. NCT00219544
  1. Calgary, Alberta
  2. Calgary, Alberta
  3. Calgary, Alberta
  4. Edmonton, Alberta
  5. Edmonton, Alberta
  6. Red Deer, Alberta
  7. Kelowna, British Columbia
  8. Vancouver, British Columbia
  9. Vancouver, British Columbia
  10. Winnipeg, Manitoba
  11. Winnipeg, Manitoba
  12. Winnipeg, Manitoba
  13. Halifax, Nova Scotia
  14. Kingston, Ontario
  15. London, Ontario
  16. Port Hope, Ontario
  17. Toronto, Ontario
  18. Charlottetown, Prince Edward Island
  19. Granby, Quebec
  20. Laval, Quebec
  21. Laval, Quebec
  22. Levis, Quebec
  23. Mirabel, Quebec
  24. Montreal, Quebec
  25. Montreal, Quebec
  26. Montreal, Quebec
  27. Sherbrooke, Quebec
  28. Sherbrook, Quebec
  29. Ste-Foy, Quebec
  30. Saskatoon, Saskatchewan
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Neuropathic PainTo Evaluate Long-Term Safety and Efficacy of Pregabalin in the Treatment of Neuropathic Pain After Spinal Cord Injury. NCT00141375
  1. Little Bay, New South Wales
  2. St. Leonards, New South Wales
  3. Warrawong, New South Wales
  4. Woolloongabba, Queensland
  5. Heidelberg, Victoria
  6. Shenton Park, Western Australia
  7. NSW,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Efficacy Study Measuring the Impact of Pregabalin on Peripheral Neuropathic Pain.
Official Title  ICMJE A Randomized, Placebo-Controlled Trial of the Efficacy and Safety of Pregabalin in the Treatment of Subjects With Peripheral Neuropathic Pain
Brief Summary This study will measure the impact of treatment with pregabalin in adult men and women who have a diagnosis of peripheral neuropathic pain (pain caused by a primary lesion of the peripheral nervous system such as Diabetic peripheral Neuropathy and Postherpetic Neuralgia).
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Neuropathic Pain
Intervention  ICMJE
  • Drug: Pregabalin (Lyrica)
    pregabalin 150mg/day (75mg BID)
  • Drug: Pregabalin (Lyrica)
    pregabalin 300 mg/day (150mg BID)
  • Drug: Pregabalin (Lyrica)
    pregabalin 600/day (300mg BID)
  • Drug: Placebo
    Placebo
Study Arms  ICMJE
  • Experimental: 1
    Intervention: Drug: Pregabalin (Lyrica)
  • Experimental: 2
    Intervention: Drug: Pregabalin (Lyrica)
  • Experimental: 3
    Intervention: Drug: Pregabalin (Lyrica)
  • Placebo Comparator: 4
    Intervention: Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 22, 2011)
158
Original Enrollment  ICMJE
 (submitted: September 13, 2005)
360
Actual Study Completion Date  ICMJE February 2008
Actual Primary Completion Date February 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Subjects presenting a diagnosis of peripheral neuropathic pain, defined as pain caused by a lesion of the peripheral nervous system manifesting with sensory symptoms and signs, for at least 6 months at screening.
  • At baseline, subjects must have completed at least 4 daily pain diaries and must have a mean weekly pain score equal or greater than 4.

Exclusion Criteria:

  • Presence of any of the following diagnoses: Cervical or lumbo-sacral radiculopathy; Operated or non-operated chronic low back pain Carpal tunnel syndrome or any other entrapment-related neuropathic pain (defined as pain associated with focal nerve lesion produced by constriction or mechanical distortion of the nerve, within a fibrous or fibro-osseous tunnel, or by a fibrous band) ; Complex regional pain syndrome (type 1 and 2); Fibromyalgia.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00219544
Other Study ID Numbers  ICMJE A0081084
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date November 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP